s6y

Lifevantage Corp

Nasdaq
LFVN
CIK
849146
Industry
Pharmaceutical Preparations
Based in
Lehi, Utah
Fiscal year ends
December 31
SEC filer category
Accelerated filer, Smaller reporting company
Employer ID (EIN)
90-0224471
Formerly
Lifeline Therapeutics, Inc., Yaak River Resources Inc

Key figures

Fiscal year to Jun 2026 Jun 2025 Jun 2024 Jun 2023 Jun 2022
Revenue $182.6M$228.5M$200.2M$213.4M$206.4M
Operating income $6.10M$12.2M$4.33M$4.26M$7.58M
Net income $5.07M$9.80M$2.94M$2.54M$3.12M
Diluted EPS $0.40$0.75$0.23$0.20$0.24
Cash from operations $10.2M$11.9M$12.2M$6.83M$7.96M
Total assets $62.1M$72.0M$60.3M$66.1M$70.7M
Shareholders’ equity $33.6M$34.6M$26.0M$34.6M$31.5M

From the company’s annual reports to the SEC. Each year links to its report.

Financials 96

  1. 10-Q Quarterly Report for period ending Sep 30, 2026
  2. 10-K Annual Report for period ending Jun 30, 2026
  3. 10-Q Quarterly Report for period ending Mar 31, 2026
  4. 10-Q Quarterly Report for period ending Dec 31, 2025
  5. 10-Q Quarterly Report for period ending Sep 30, 2025
  6. 10-K Annual Report for period ending Jun 30, 2025
  7. 10-Q Quarterly Report for period ending Mar 31, 2025
  8. 10-Q Quarterly Report for period ending Dec 31, 2024
  9. 10-Q Quarterly Report for period ending Sep 30, 2024
  10. 10-K Annual Report for period ending Jun 30, 2024

All 96 financials filings

News 301

  1. 8-K Shareholder vote results
  2. 8-K Financial results
  3. 8-K Charter or bylaw change
  4. 8-K Financial results
  5. 8-K Director or officer change
  6. 8-K Financial results
  7. 8-K Director or officer change
  8. 8-K Financial results; Director or officer change
  9. 8-K Director or officer change
  10. 8-K Shareholder vote results

All 301 news filings

Ownership 719

  1. 4 Change in insider ownership
  2. 144 Notice of proposed sale of restricted stock
  3. 4 Change in insider ownership
  4. 4 Change in insider ownership
  5. 4 Change in insider ownership
  6. 4 Change in insider ownership
  7. 4 Change in insider ownership
  8. SCHEDULE 13G/A Major shareholder report (passive investor)
  9. 4 Change in insider ownership
  10. 4 Change in insider ownership

All 719 ownership filings

Prospectus 29

  1. S-8 Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
  2. S-3 Registration statement for specified transactions by certain issuers
  3. S-8 Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
  4. S-8 Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
  5. S-8 Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
  6. S-3 Registration statement for specified transactions by certain issuers
  7. S-8 Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
  8. S-3 Registration statement for specified transactions by certain issuers
  9. S-8 Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
  10. S-8 Initial registration statement for securities to be offered to employees pursuant to employee benefit plans

All 29 prospectus filings

Proxies 69

  1. DEFA14A Definitive additional proxy soliciting materials including Rule 14(a)(12) material. Note: Submission type DEFA14A can be filed as part of Form 8-K. For filers subject to 8-K filing requirements, we recommend the use of the 8-K combined form type as the easiest method for fulfilling your filing requirement for both forms.
  2. DEF 14A Definitive proxy statements
  3. DEFA14A Definitive additional proxy soliciting materials including Rule 14(a)(12) material. Note: Submission type DEFA14A can be filed as part of Form 8-K. For filers subject to 8-K filing requirements, we recommend the use of the 8-K combined form type as the easiest method for fulfilling your filing requirement for both forms.
  4. DEF 14A Definitive proxy statements
  5. DEFA14A Definitive additional proxy soliciting materials including Rule 14(a)(12) material. Note: Submission type DEFA14A can be filed as part of Form 8-K. For filers subject to 8-K filing requirements, we recommend the use of the 8-K combined form type as the easiest method for fulfilling your filing requirement for both forms.
  6. DEF 14A Definitive proxy statements
  7. DFAN14A Definitive additional proxy soliciting materials filed by non-management including Rule 14(a)(12) material
  8. DFAN14A Definitive additional proxy soliciting materials filed by non-management including Rule 14(a)(12) material
  9. DEFA14A Definitive additional proxy soliciting materials including Rule 14(a)(12) material. Note: Submission type DEFA14A can be filed as part of Form 8-K. For filers subject to 8-K filing requirements, we recommend the use of the 8-K combined form type as the easiest method for fulfilling your filing requirement for both forms.
  10. DFAN14A Definitive additional proxy soliciting materials filed by non-management including Rule 14(a)(12) material

All 69 proxies filings

Other 105

  1. ARS Annual report to security holders
  2. EFFECT Notice of Effectiveness
  3. CORRESP A correspondence can be sent as a document with another submission type or can be sent as a separate submission.
  4. UPLOAD Letter (PDF)
  5. ARS Annual report to security holders
  6. ARS Annual report to security holders
  7. UPLOAD Letter (PDF)
  8. ARS Annual report to security holders
  9. 8-A12B Form for the registration / listing of a class of securities on a national securities exchange pursuant to Section 12(b)
  10. EFFECT Notice of Effectiveness

All 105 other filings

Others in Pharmaceutical Preparations

Every company in this industry